VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
Europe - FRA:VX1 - US92532F1003 - Common Stock
372.25 EUR
+6 (+1.64%)
Overall VX1 gets a fundamental rating of 7 out of 10. We evaluated VX1 against 74 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make VX1 a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year VX1 was profitable.
In the past year VX1 had a positive cash flow from operations.
VX1 had positive earnings in 4 of the past 5 years.
VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
VX1 has a better Return On Assets (15.13%) than 89.19% of its industry peers.
Looking at the Return On Equity, with a value of 21.18%, VX1 belongs to the top of the industry, outperforming 91.89% of the companies in the same industry.
With an excellent Return On Invested Capital value of 15.66%, VX1 belongs to the best of the industry, outperforming 93.24% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for VX1 is above the industry average of 12.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| ROIC | 15.66% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
1.3 Margins
The Profit Margin of VX1 (31.86%) is better than 89.19% of its industry peers.
VX1 has a Operating Margin of 38.77%. This is amongst the best in the industry. VX1 outperforms 93.24% of its industry peers.
VX1's Operating Margin has improved in the last couple of years.
VX1 has a better Gross Margin (86.11%) than 79.73% of its industry peers.
VX1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.77% | ||
| PM (TTM) | 31.86% | ||
| GM | 86.11% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
VX1 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
VX1 has less shares outstanding than it did 5 years ago.
The debt/assets ratio for VX1 has been reduced compared to a year ago.
2.2 Solvency
VX1 has an Altman-Z score of 11.72. This indicates that VX1 is financially healthy and has little risk of bankruptcy at the moment.
VX1's Altman-Z score of 11.72 is amongst the best of the industry. VX1 outperforms 89.19% of its industry peers.
VX1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.72 |
ROIC/WACC1.79
WACC8.77%
2.3 Liquidity
A Current Ratio of 2.52 indicates that VX1 has no problem at all paying its short term obligations.
VX1 has a Current ratio (2.52) which is comparable to the rest of the industry.
A Quick Ratio of 2.16 indicates that VX1 has no problem at all paying its short term obligations.
VX1 has a Quick ratio (2.16) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 3303.92% over the past year.
The earnings per share for VX1 have been decreasing by -44.14% on average. This is quite bad
VX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.33%.
VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
3.2 Future
Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 149.22% on average per year.
The Revenue is expected to grow by 9.58% on average over the next years. This is quite good.
EPS Next Y6237.82%
EPS Next 2Y744.13%
EPS Next 3Y327.84%
EPS Next 5Y149.22%
Revenue Next Year10.08%
Revenue Next 2Y9.82%
Revenue Next 3Y9.46%
Revenue Next 5Y9.58%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 24.82, VX1 is valued on the expensive side.
VX1's Price/Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 81.08% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.34, VX1 is valued at the same level.
Based on the Price/Forward Earnings ratio of 20.85, the valuation of VX1 can be described as rather expensive.
VX1's Price/Forward Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 89.19% of the companies in the same industry.
VX1's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 34.43.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.82 | ||
| Fwd PE | 20.85 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VX1 indicates a somewhat cheap valuation: VX1 is cheaper than 78.38% of the companies listed in the same industry.
VX1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VX1 is cheaper than 82.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.57 | ||
| EV/EBITDA | 22.19 |
4.3 Compensation for Growth
VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VX1 has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VX1's earnings are expected to grow with 327.84% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y744.13%
EPS Next 3Y327.84%
5. Dividend
5.1 Amount
VX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:VX1 (11/12/2025, 7:00:00 PM)
372.25
+6 (+1.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.11%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap95.44B
Revenue(TTM)11.72B
Net Income(TTM)3.64B
Analysts76.41
Price Target418.33 (12.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.78%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.35%
EPS beat(12)7
Avg EPS beat(12)-42%
EPS beat(16)10
Avg EPS beat(16)-30.64%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)-0.01%
PT rev (3m)-3.86%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)-0.98%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)0.41%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.82 | ||
| Fwd PE | 20.85 | ||
| P/S | 9.68 | ||
| P/FCF | 31.57 | ||
| P/OCF | 28.72 | ||
| P/B | 6.43 | ||
| P/tB | 7.06 | ||
| EV/EBITDA | 22.19 |
EPS(TTM)15
EY4.03%
EPS(NY)17.85
Fwd EY4.8%
FCF(TTM)11.79
FCFY3.17%
OCF(TTM)12.96
OCFY3.48%
SpS38.47
BVpS57.87
TBVpS52.74
PEG (NY)0
PEG (5Y)N/A
Graham Number139.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| ROCE | 22.25% | ||
| ROIC | 15.66% | ||
| ROICexc | 23.06% | ||
| ROICexgc | 25.99% | ||
| OM | 38.77% | ||
| PM (TTM) | 31.86% | ||
| GM | 86.11% | ||
| FCFM | 30.65% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 173.52% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | 260.41 | ||
| Cash Conversion | 83.13% | ||
| Profit Quality | 96.21% | ||
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.16 | ||
| Altman-Z | 11.72 |
F-Score6
WACC8.77%
ROIC/WACC1.79
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6237.82%
EPS Next 2Y744.13%
EPS Next 3Y327.84%
EPS Next 5Y149.22%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.08%
Revenue Next 2Y9.82%
Revenue Next 3Y9.46%
Revenue Next 5Y9.58%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year820.09%
EBIT Next 3Y129.43%
EBIT Next 5Y68.42%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.
What is the valuation status of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Undervalued.
What is the profitability of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 24.82 and the Price/Book (PB) ratio is 6.43.
What is the financial health of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 9 / 10.